Namuscla
Namuscla Uses, Dosage, Side Effects, Food Interaction and all others data.
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Namuscla is a local anesthetic, antiarrhythmic agent (Class Ib), structurally similar to lidocaine, but orally active. Namuscla has fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. It shortens the action potential duration, reduces refractoriness, and decreases Vmax in partially depolarized cells with fast response action potentials. Namuscla either does not change the action potential duration, or decreases the action potential duration.
| Trade Name | Namuscla |
| Availability | Prescription only |
| Generic | Mexiletine |
| Mexiletine Other Names | Mexiletina, Mexilétine, Mexiletine, Mexiletinum |
| Related Drugs | propranolol, atenolol, amiodarone, lidocaine, verapamil, flecainide, Tenormin, Inderal, dofetilide |
| Type | Capsule |
| Formula | C11H17NO |
| Weight | Average: 179.2588 Monoisotopic: 179.131014171 |
| Protein binding | 50-60% |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Lupin Healthcare (UK) Ltd |
| Available Country | United Kingdom |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Namuscla is a class 1B antiarrhythmic agent used in the treatment of documented ventricular arrhythmias that warrant treatment.
For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
Namuscla is also used to associated treatment for these conditions: Severe Ventricular tachycardia, Severe ventricular arrhythmias
How Namuscla works
Namuscla, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Namuscla decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals
Toxicity
Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.
Food Interaction
- Take with food. Food reduces irritation.
Namuscla Drug Interaction
Moderate: duloxetineMinor: ascorbic acid, ascorbic acidUnknown: aspirin, aspirin, aspirin, aspirin, apixaban, apixaban, sacubitril / valsartan, sacubitril / valsartan, atorvastatin, pregabalin, pregabalin, metoprolol, metoprolol, cyanocobalamin, cyanocobalamin, cholecalciferol, cholecalciferol
Namuscla Disease Interaction
Major: cardiovascular dysfunction, proarrhythmic effects, AV node dysfunctionModerate: liver disease, renal dysfunction, seizures
Volume of Distribution
- 5 to 7 L/lg
Elimination Route
Well absorbed (bioavailability 90%) from the gastrointenstinal tract.
Half Life
10-12 hours
Elimination Route
Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%.
Innovators Monograph
You find simplified version here Namuscla
